Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
Shuang Wang, Yun Peng, Rongjuan Wang, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

The signal pathways and treatment of cytokine storm in COVID-19
Lan Yang, Xueru Xie, Zikun Tu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 496
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Qianqian Zhang, Rong Xiang, Shanshan Huo, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 300
Neutralizing Antibody Therapeutics for COVID-19
Aeron C. Hurt, Adam K. Wheatley
Viruses (2021) Vol. 13, Iss. 4, pp. 628-628
Open Access | Times Cited: 117
Neutralizing antibodies for the prevention and treatment of COVID-19
Lanying Du, Yang Yang, Xiujuan Zhang
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 10, pp. 2293-2306
Open Access | Times Cited: 117
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 117
In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients
Raquel Rubio‐Acero, Noemi Castelletti, Volker Fingerle, et al.
Infectious Diseases and Therapy (2021) Vol. 10, Iss. 3, pp. 1505-1518
Open Access | Times Cited: 60
Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2
Wael Bahnan, Sebastian Wrighton, Martin Sundwall, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 53
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
Reza Elahi, Parsa Karami, Amir Hossein Heidary, et al.
International Immunopharmacology (2022) Vol. 105, pp. 108536-108536
Open Access | Times Cited: 43
Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
Shuang Wang, Junchao Wang, Xiaojuan Yu, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 39
Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells
Jun Shimizu, Tadahiro Sasaki, Ritsuko Koketsu, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 37
SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo
Emi E. Nakayama, Tatsuo Shioda
Microorganisms (2023) Vol. 11, Iss. 4, pp. 1015-1015
Open Access | Times Cited: 21
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Pauline Maisonnasse, Yoann Aldon, Aurélien Marc, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 51
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
Matthew D. Hall, James M. Anderson, Annaliesa S. Anderson, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. Supplement_1, pp. S1-S21
Open Access | Times Cited: 41
Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis
Swapna Thomas, Maria K. Smatti, Allal Ouhtit, et al.
Molecular Immunology (2022) Vol. 152, pp. 172-182
Open Access | Times Cited: 36
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 31
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Jordan J. Clark, Irene Hoxie, Daniel C. Adelsberg, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Shen Wang, Wujian Li, Zhenshan Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
How Broadly Neutralising Antibodies Are Redefining Immunity to Influenza
Rebecca Steventon, Lucas Stolle, Craig Thompson
Antibodies (2025) Vol. 14, Iss. 1, pp. 4-4
Open Access
Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development
Vincenzo Lionetti, Sveva Bollini, Raffaele Coppini, et al.
Pharmacological Research (2021) Vol. 168, pp. 105581-105581
Open Access | Times Cited: 34
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Jingjing Zhang, Han Zhang, Litao Sun
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion
Chia‐Jung Li, Tai‐Ling Chao, Ting-Yu Chang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 22
Aptamer‐based strategies against SARS‐CoV‐2 viruses
Yihao Huang, Ximing Chen, Jialü Zhang, et al.
BMEMat (2023) Vol. 1, Iss. 3
Open Access | Times Cited: 12
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 11
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Jordan Clark, Irene Hoxie, Daniel C. Adelsberg, et al.
Cell Reports (2024) Vol. 43, Iss. 11, pp. 114922-114922
Open Access | Times Cited: 3
COVID-19 Research: Lessons from Non-Human Primate Models
Laure Albrecht, Elodie Bishop, Basile Jay, et al.
Vaccines (2021) Vol. 9, Iss. 8, pp. 886-886
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top